DK1187635T3 - Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist - Google Patents

Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist

Info

Publication number
DK1187635T3
DK1187635T3 DK00940519T DK00940519T DK1187635T3 DK 1187635 T3 DK1187635 T3 DK 1187635T3 DK 00940519 T DK00940519 T DK 00940519T DK 00940519 T DK00940519 T DK 00940519T DK 1187635 T3 DK1187635 T3 DK 1187635T3
Authority
DK
Denmark
Prior art keywords
alpha
adrenergic agonist
nmda antagonist
anesthetic formulation
formulation
Prior art date
Application number
DK00940519T
Other languages
Danish (da)
English (en)
Inventor
Nicholas Peter Imperial Franks
Mervyn Imperial Coll Scho Maze
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10855216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1187635(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Application granted granted Critical
Publication of DK1187635T3 publication Critical patent/DK1187635T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK00940519T 1999-06-11 2000-06-09 Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist DK1187635T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9913677.2A GB9913677D0 (en) 1999-06-11 1999-06-11 Formulation
PCT/GB2000/002271 WO2000076545A1 (en) 1999-06-11 2000-06-09 Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist

Publications (1)

Publication Number Publication Date
DK1187635T3 true DK1187635T3 (da) 2004-06-21

Family

ID=10855216

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00940519T DK1187635T3 (da) 1999-06-11 2000-06-09 Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist

Country Status (14)

Country Link
US (1) US6562855B1 (ja)
EP (1) EP1187635B1 (ja)
JP (1) JP2003529541A (ja)
AT (1) ATE259658T1 (ja)
AU (1) AU778671B2 (ja)
CA (1) CA2376916C (ja)
DE (1) DE60008374T2 (ja)
DK (1) DK1187635T3 (ja)
ES (1) ES2215678T3 (ja)
GB (2) GB9913677D0 (ja)
PT (1) PT1187635E (ja)
RU (1) RU2244558C2 (ja)
WO (1) WO2000076545A1 (ja)
ZA (1) ZA200110116B (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use
EP1515732B1 (de) 2002-06-12 2009-01-14 Air Liquide Deutschland GmbH Cerebrale protektion mit einem xenonhaltigen gas
AU2003249959A1 (en) * 2002-07-05 2004-01-23 Messer Griesheim Gmbh Adjuvant containing xenon
AU2003288214A1 (en) * 2002-12-06 2004-06-30 Michael Georgieff Nasal pharmaceutical preparation containing an active lipophilic liquid or gaseous ingredient
EP1675597A2 (en) * 2003-10-21 2006-07-05 Aga Ab Use of xenon for the prevention of programmed cell death
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
US20100022574A1 (en) * 2008-07-28 2010-01-28 EndogenX, Inc. Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
JP5671459B2 (ja) 2008-08-01 2015-02-18 アイ・セラピーズ・エル・エル・シー 血管収縮組成物および使用方法
US20110244058A1 (en) * 2008-08-01 2011-10-06 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
WO2010132882A2 (en) * 2009-05-15 2010-11-18 Recro Pharma, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US20110152271A1 (en) * 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
NZ703808A (en) * 2010-01-08 2016-01-29 Recro Pharma Inc Topical transdermal dexmedetomidine compositions and methods of use thereof
CA2796280A1 (en) * 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill Universit Y Topical treatments for pain
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
BR112014019171A8 (pt) 2011-12-11 2017-07-11 Recro Pharma Inc Composições intranasais de dexdetomida e seus métodos de uso
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
US20160030470A1 (en) 2013-03-15 2016-02-04 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
JP6188933B2 (ja) 2013-10-07 2017-08-30 テイコク ファーマ ユーエスエー インコーポレーテッド 非鎮静量のデクスメデトミジンの経皮送達用方法及び組成物
CN106456561B (zh) 2013-10-07 2020-02-28 帝国制药美国公司 使用右旋美托咪啶经皮组合物治疗注意力缺陷多动症、焦虑症和失眠症的方法和组合物
TWI704933B (zh) 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
RU2557882C1 (ru) * 2014-07-08 2015-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Способ проведения премедикации при плановом хирургическом лечении
WO2017139382A1 (en) * 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859685A (en) * 1986-08-13 1989-08-22 Boc, Inc. Anesthetic composition and method of using the same
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
EP0861329B1 (fr) 1995-11-13 2005-03-16 Commissariat A L'energie Atomique Complexe proteique dodecaedrique adenoviral, composition le contenant et ses applications
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
FR2787713A1 (fr) * 1998-12-23 2000-06-30 Johan Huysman Composition en tant que medicament et utilisation d'une telle composition pour l'obtention d'un medicament destine a l'anesthesie, notamment medicament analgesique
DE19910986C2 (de) 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist

Also Published As

Publication number Publication date
JP2003529541A (ja) 2003-10-07
EP1187635B1 (en) 2004-02-18
PT1187635E (pt) 2004-07-30
ES2215678T3 (es) 2004-10-16
GB2352633B (en) 2002-04-17
AU778671B2 (en) 2004-12-16
CA2376916A1 (en) 2000-12-21
ZA200110116B (en) 2003-07-23
US6562855B1 (en) 2003-05-13
GB9913677D0 (en) 1999-08-11
RU2244558C2 (ru) 2005-01-20
DE60008374D1 (de) 2004-03-25
AU5544400A (en) 2001-01-02
GB2352633A (en) 2001-02-07
GB0014165D0 (en) 2000-08-02
ATE259658T1 (de) 2004-03-15
WO2000076545A1 (en) 2000-12-21
DE60008374T2 (de) 2004-12-09
EP1187635A1 (en) 2002-03-20
CA2376916C (en) 2010-09-21

Similar Documents

Publication Publication Date Title
DK1187635T3 (da) Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist
NO20024309D0 (no) Intradermal penetreringsmidler for topikal lokal anestetisk administrering
NO20040968L (no) Opioidagonistpreparater med frigjorbar og sekvestrert antagonist
DK1280531T3 (da) Formulering bestående af phentolaminmesylat og anvendelse heraf
EE9700192A (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja antatsiidainet või alginaati
EE9700195A (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja prokineetilist ainet
DE60044041D1 (de) Exendine zur Glucagon Suppression
RS50407B (sr) Oralne formulacije opijatnog agonista otporne na mehaničke,termičke i/ili hemijske promene fizičkih osobina doznog oblika
DE60216078D1 (de) Opioid enthaltende arzneiform gegen missbrauch
EE04003B1 (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja NSAID
DK1191926T3 (da) Ny omeprazol- og (S)-omeprazolformulering
EA199700230A1 (ru) Дозирующий ингалятор для дипропионата беклометазона
MY129356A (en) Electrospun pharmaceutical compositions
RS52283B (sr) 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n- metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2- indolinon-monoetansulfonat i njegova primena u farmaceutskoj kompoziciji
IS7111A (is) Lyfjablanda sem felur í sér róteindadæluhemil og sýrubindandi efni
NO20004215D0 (no) Et farmasøytisk preparat som omfatter en angiotensin II type 2-reseptoragonist, og anvendelse derav
GEP20074047B (en) Pramipexole once-daily dosage form
ES2157881T3 (es) Metanosulfonato de paroxetina.
CY1105211T1 (el) Φαρμακευτικοι συνδυασμοι που πepιλαμβανουν εναν ανταγωνιστη του υποδοχεα p2τ και μελαγατρανη
DE60019334D1 (de) Antivirale arznei
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
AU2001287698A1 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
NO20010537D0 (no) Farmasöytiske preparater omfattende ibuprofen og domperidon
CY1108502T1 (el) Ελεγχομενης-αποδεσμευσης συνθεσεις οι οποιες περιεχουν οπιοειδη αγωνιστη και ανταγωνιστη